Analysts take a look at GW Pharmaceuticals plc (NASDAQ:GWPH) having this to say.

April 26, 2018 - By Adrian Mccoy

GW Pharmaceuticals plc (NASDAQ:GWPH) Ratings Coverage

Among 5 analysts covering GW Pharmaceuticals Plc – American Depositary Shares (NASDAQ:GWPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. GW Pharmaceuticals Plc – American Depositary Shares had 10 analyst reports since November 14, 2017 according to SRatingsIntel. The firm has “Buy” rating by Bank of America given on Tuesday, February 6. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Buy” rating given on Monday, February 5 by Cantor Fitzgerald. The rating was maintained by Cowen & Co with “Buy” on Wednesday, April 18. Cantor Fitzgerald maintained it with “Buy” rating and $19200 target in Tuesday, April 17 report. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Outperform” rating given on Tuesday, February 6 by Leerink Swann. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) earned “Buy” rating by Leerink Swann on Tuesday, January 23. Goldman Sachs upgraded GW Pharmaceuticals plc (NASDAQ:GWPH) rating on Thursday, December 14. Goldman Sachs has “Buy” rating and $174.0 target. On Tuesday, November 14 the stock rating was maintained by Bank of America with “Buy”. Leerink Swann maintained GW Pharmaceuticals plc (NASDAQ:GWPH) on Thursday, December 28 with “Buy” rating. Cantor Fitzgerald maintained it with “Buy” rating and $208.0 target in Monday, December 4 report. Below is a list of GW Pharmaceuticals plc (NASDAQ:GWPH) latest ratings and price target changes.

18/04/2018 Broker: Cowen & Co Rating: Buy New Target: $165.0000 Maintain
17/04/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $192.0000 Maintain
06/02/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $154 New Target: $149 Maintain
06/02/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $153 New Target: $157 Maintain
05/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $192.0 Maintain
23/01/2018 Broker: Leerink Swann Rating: Buy New Target: $153.0 Maintain
28/12/2017 Broker: Leerink Swann Rating: Buy Maintain
14/12/2017 Broker: Goldman Sachs Rating: Buy New Target: $174.0 Upgrade
04/12/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $208.0 Maintain
14/11/2017 Broker: Bank of America Rating: Buy Old Target: $160 New Target: $158 Maintain

The stock decreased 0.46% or $0.64 during the last trading session, reaching $137.95. About 310,935 shares traded. GW Pharmaceuticals plc (NASDAQ:GWPH) has declined 9.18% since April 26, 2017 and is downtrending. It has underperformed by 20.73% the S&P500.

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company has market cap of $3.89 billion. It operates through three divisions: Commercial, Sativex Research and Development, and Pipeline Research and Development. It currently has negative earnings. The firm markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis.

GW Pharmaceuticals plc (NASDAQ:GWPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.